ENPP2 and cystic fibrosis: Clinical trials demonstrated that ATX and LPA1 receptor antagonists are promising candidates for the treatment of fibrotic and inflammatory conditions, specifically idiopathic pulmonary fibrosis, systemic sclerosis, and cystic fibrosis [84,85].